Clinical trial · Observational
Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.
SALTO-BIO (Long Term Follow up in Oncology) - PanCareLIFE. Long Term Support for Pediatric Cancer Survivors in Rhône-Alpes. Evaluation of Women Fertility.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to patients a quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pediatric cancer women survivors | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pediatric cancer women survivors
- description
- Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
- interventionNames
- Other: Pediatric cancer women survivors
Primary outcomes (3)
- measure
- Measure the FSH hormone rate.
- timeFrame
- Day 1
- description
- In this arm women will incur a blood taking to measure the FSH hormone rate.
- measure
- Measure the AMH hormone rate.
- timeFrame
- Day 1
- description
- In this arm women will incur a blood taking to measure the AMH hormone rate.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * min 18 years old * female * diagnosed for a cancer between 01/01/87 and 31/12/99, before 15 years old, and living in Rhône-Alpes * treated with chemotherapy +/- radiotherapy * accepting a blood taking to perform DNA and hormonal tests * affiliated to a security social scheme * informed consent Exclusion Criteria: \- severe mental disorder
References
Publications (0)
Data not yet available